A second biosimilar to Amgen’s Neupogen, which treats neutropenia, has been approved in the United States. The FDA approved Pfizer’s filgrastim-aafi, which will be sold under the brand name Nivestym.

The Food and Drug Administration has approved its first biosimilar, Zarxio (filgrastim-sndz), for all five of its counterpart Neupogen's authorized indications. The Food and Drug Administration has ...

The speed and extent of biosimilar penetration differ across provider types. Provider awareness and incentives are significantly associated with biosimilar uptake. ABSTRACTObjectives: To identify ...

Biosimilars are likely to rival name-brand treatments for breast and other cancers, and the competition could drive prices down. What’s new about the recently approved medication Zarxio? Nothing — and ...

A unanimous U.S. Supreme Court has handed biosimilar developers a key victory that could generate millions in future sales by ruling that they can bring their treatments to market upon FDA approval ...

Abstract PURPOSE: This multicenter, randomized, double-blind, active-control study was designed to determine whether a single subcutaneous injection of pegfilgrastim (SD/01, sustained-duration ...

PURPOSE: This multicenter, randomized, double-blind, active-control study was designed to determine whether a single subcutaneous injection of pegfilgrastim (SD/01, sustained-duration filgrastim; 100 ...